The Irish arm of US biopharmaceutical company Amgen has invested $407m (€353.3m) in capital expenditure on its Dun Laoghaire manufacturing facility over two years, according to newly filed company accounts. RTÉ reported on the filings, which show the investment was directed at the installation, construction, and testing of manufacturing facilities at the south Dublin site.

Accounts filed by Amgen Technology Ireland UC show that $224.2m (€194.6m) was spent on capital expenditure at the facility in 2024, following a spend of $182.8m (€158.7m) under the same heading in 2023.

The accounts show pre-tax profits at the firm increased by 10% to $824.43m (€715.9m) for 2024, with revenues rising 41% from $3.97 billion (€3.45 billion) to $5.62 billion (€4.88 billion).

The company is continuing to expand its south Dublin workforce, with numbers employed increasing by 78 from 953 to 1,031 in 2024. The firm is projecting a total workforce of 2,888 at the Dun Laoghaire site by 2035, an increase of over 1,000.

Planning documents lodged with Dun Laoghaire Rathdown County Council reveal plans for an additional 1,087 new car spaces, comprising a six-storey 853-space car park and 234 surface car spaces, to support the planned expansion.

The accounts also note that the company expects to recognise a $1 billion (€868.6m) impairment loss for 2025 relating to its Otezla medicine, following its inclusion in the US Medicare Drug Price Negotiation Programme under the Inflation Reduction Act, earlier than anticipated.

Shareholder funds at end of December 2024 totalled $4.8 billion (€4.17 billion), including accumulated profits of $2.27 billion (€1.97 billion).

Access the full report on Amgen's Dun Laoghaire manufacturing investment here.